Clinical Trial Update: A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial of rapastinel for rapid treatment of depression and suicidality in major depressive disorder was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Rapastinel (Rapastinel)

Snippet

Sponsor: Naurex, Inc, an affiliate of Allergan plc | Conditions: Depressive Disorder, Major | Phase 2 | Status: TERMINATED | Results posted: 2020-08-14